Your browser doesn't support javascript.
loading
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
Lee, Keun-Wook; Van Cutsem, Eric; Bang, Yung-Jue; Fuchs, Charles S; Kudaba, Iveta; Garrido, Marcelo; Chung, Hyun Cheol; Lee, Jeeyun; Castro, Hugo R; Chao, Joseph; Wainberg, Zev A; Cao, Z Alexander; Aurora-Garg, Deepti; Kobie, Julie; Cristescu, Razvan; Bhagia, Pooja; Shah, Sukrut; Tabernero, Josep; Shitara, Kohei; Wyrwicz, Lucjan.
  • Lee KW; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Van Cutsem E; Department of Digestive Oncology, University Hospitals Gasthuisberg and University of Leuven, Leuven, Belgium.
  • Bang YJ; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Fuchs CS; Department of Internal Medicine, Yale Cancer Center, Smilow Cancer Hospital, New Haven, Connecticut.
  • Kudaba I; Department of Medical Oncology, Latvian Oncology Center Rakus Gailezers, Riga, Latvia.
  • Garrido M; Department of Hematology and Oncology, Pontifical Catholic University of Chile, Santiago, Chile.
  • Chung HC; Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Lee J; Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea.
  • Castro HR; Department of Medical Oncology, Angeles Medical Group, Guatemala City, Guatemala.
  • Chao J; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California.
  • Wainberg ZA; David Geffen School of Medicine at the University of California, Los Angeles, California.
  • Cao ZA; Merck & Co., Inc., Rahway, New Jersey.
  • Aurora-Garg D; Merck & Co., Inc., Rahway, New Jersey.
  • Kobie J; Merck & Co., Inc., Rahway, New Jersey.
  • Cristescu R; Merck & Co., Inc., Rahway, New Jersey.
  • Bhagia P; Merck & Co., Inc., Rahway, New Jersey.
  • Shah S; Merck & Co., Inc., Rahway, New Jersey.
  • Tabernero J; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain.
  • Shitara K; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Wyrwicz L; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Clin Cancer Res ; 28(16): 3489-3498, 2022 08 15.
Article en En | MEDLINE | ID: mdl-35657979
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Humanizados Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Humanizados Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article